The above-mentioned IDH mutation has been considered to be the most clinically relevant glioma marker since its observation by Parson et al. in 2008 and its recognition as the earliest genetic event driver in gliomagenesis [5,6]. This evidence concerns the gene IDH2 and central nervous system cancer.